REGULATORY

Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash

January 21, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Novartis Pharma’s asthma drug Xolair (omalizumab) will become the first drug to face a new special re-pricing rule to be introduced in April after its label expansion to pollen allergy last December, while MSD’s I/O star Keytruda (pembrolizumab) will get…

To read the full story

Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020

REGULATORY

MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
Cabinet OKs Subsidy to Boost Antibiotic API Stockpiles, Allocates 7.1 Billion Yen from Reserve
January 21, 2026
PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…